Incidence and Risk Factors of Venous Thromboembolism in Patients After Transurethral Resection of the Prostate (TURP)

Zhihuan Zheng \(^{1*}\), Ziqiang Wu \(^{1*}\), Kaixuan Li \(^{1}\), Quan Zhu \(^{1}\), Haozhen Li \(^{1}\), Xuesong Liu \(^{1}\), Guilin Wang \(^{1}\), Zhengyan Tang \(^{1,2}\) and Zhao Wang \(^{1*}\)

\(^{1}\) Xiangya Hospital, Central South University, Changsha, China, \(^{2}\) Provincial Laboratory for Diagnosis and Treatment of Genitourinary System Disease, Changsha, China

**Objective:** Venous thromboembolism (VTE) in patients following transurethral resection of the prostate (TURP) has been overlooked for many years. This research was aimed to investigate the incidence and risk factors of VTE in patients after TURP.

**Methods:** A total of 451 patients who underwent TURP between January 2017 and December 2020 were retrospectively analyzed. Clinical data of the patients were collected, such as basic demographic data, prostate volume, creatinine values, hemoglobin values, surgery duration, Caprini score, international prostate symptom score (IPSS), quality of life (QOL) score, plasma D-dimer levels, and so on. Univariate analysis and multivariate logistic regression were performed to identify the potential risk factors of VTE. Venous ultrasonography of lower extremities was performed routinely to detect VTE for patients after TURP.

**Results:** In total, 36 (8%) out of the 451 patients suffered from VTE. A total of 12 (2.7%) patients were confirmed with deep venous thrombosis (DVT). Two patients (0.4%) were identified with pulmonary embolism (PE). Twenty-two (4.9%) patients were suffered from superficial venous thrombosis. Furthermore, according to the results of multivariate stepwise logistic regression analysis, having a history of VTE (adjusted odds ratio [aOR] = 10.980, 95% CI = 2.265–53.223), complicated with postoperative bladder hematoma (aOR = 6.302, 95% CI = 2.265–17.532), D-dimer > 1.25 mg/L (aOR = 4.402, 95% CI = 1.798–10.774), and age > 65 (aOR = 3.106, 95% CI = 1.084–8.893) were independent risk factors of VTE after TURP. In addition, the nomogram prediction model is a useful auxiliary prevention tool of VTE.

**Conclusion:** The incidence of VTE is severely underestimated in patients following TURP. A lot of asymptomatic VTEs have been overlooked. Early detection and diagnosis of VTE are essential. Nevertheless, further verifications based on the results of large-scaled studies are still needed.

**Keywords:** benign prostatic hyperplasia, incidence, risk factors, venous thromboembolism, TURP
INTRODUCTION

Benign prostatic hyperplasia (BPH) is one of the most common benign diseases causing dysuria in elderly men. Approximately, 50% of men over 50 years have evidence of BPH and by the time they are 80 years old, the proportion of men with BPH increases to 80% (1). For decades, the gold standard for surgical treatment of BPH remains transurethral resection of the prostate (TURP). While, this procedure carries the risk of bleeding, clot treatment of BPH remains transurethral resection of the prostate (TURP). While, this procedure carries the risk of bleeding, clot

In clinical practice, urologists are more concerned about the abovementioned risks, but little attention has been paid to the risk of venous thromboembolism (VTE). VTE, which consists of vein thrombosis (DVT) and pulmonary embolism (PE), was a potentially fatal complication after surgery (3). Thirty-day mortality of the VTE patients can reach more than 10-fold of the non-VTE patients (4) and about 30% of patients with PE die within the first year after diagnosis (5). Recent studies on VTE in urological non-oncological patients demonstrate that the incidence of VTE is not as rare as previously reported (6–9). Few studies have been concerned about the incidence and risk factors of VTE in patients following TURP. So, in this study, we aimed to retrospectively investigate the incidence and risk factors of VTE in recent years in our institution after TURP.

METHODS

 Patients
We retrospectively collected the clinical data of patients who underwent TURP in our institution, a tertiary hospital with the highest level of referral directly under the National Healthy Committee of China. The data were obtained through Electronic Medical Record System (EMRS). The inclusion criteria were as follows: (1) patients who were eligible for TURP from January 2017 to December 2020; (2) more than 18 years of age. The following were exclusion criteria: (1) complicated with active malignant disease; (2) having a history of prostate surgery or urinary reconstructive surgery; (3) postoperative pathological examination revealing prostate cancer; (4) physical condition was inappropriate to perform TURP (such as poor cardiopulmonary function and poor coagulation function); and (5) VTE was found preoperatively in the lower extremities by ultrasound.

Thrombosis Prevention
The risk of VTE of the inpatients was assessed by the Caprini score when admission. If the patients were intermediate-risk or high-risk, mechanical thromboprophylaxis (graduated compression stockings and intermittent pneumatic compression device) was used after surgery. Pharmacological prophylaxis was not regularly performed according to the recommendation of the European Association of Urology (EAU) guidelines and the American Society of Hematology guidelines (10, 11).

Diagnosis and Treatment of VTE
Ultrasound for bilateral lower extremities was performed preoperatively and postoperatively in intermediate-risk and high-risk patients. Incompressibility intravascular defects or absences of phase Doppler signal were identified as positive of VTE (12). The diagnosis of PE was established by the VTE group in our institution according to either computed tomographic pulmonary arteriography (CTPA), echocardiography or suspicious symptoms of PE, such as dyspnea, palpitation, and/or pleuritic chest pain developed after surgery. Postoperative hemoglobin and plasma D-dimer concentration were measured within 24 h after surgery. Other biochemical indicators were measured within 24 h after admission. Once the patient was diagnosed with VTE, the mechanical thromboprophylaxis was quit immediately. Then, the patient will be treated under the guidance of interdisciplinary consultation. Three months of anticoagulant with rivaroxaban was maintained after discharge according to the actual condition. Vascular ultrasonography would be re-performed 3 months later.

Data Analysis
Categorical variables were presented as percentages (%) and analyzed using the chi-squared or Fisher’s exact tests, as appropriate. Quantitative data were presented as mean ± SD or median (interquartile intervals) and analyzed by Student’s t or the Mann-Whitney U test, as appropriate. Univariate, multivariate logistic regression models, and multivariate stepwise logistic regression models were performed to identify the risk factors for VTE after TURP. A two-tailed p < 0.05 was considered statistically significant. All statistical analyses were performed by IBM SPSS Statistics for Windows, version 25.0 (IBM Corp, Armonk, NY, USA) and R version 4.1.0.

RESULTS

Incidence
A total of 451 patients who underwent TURP were enrolled in the study. There were 8.0% (36/451) patients found with VTE. In total, 2.7% (12/451) of the patients were diagnosed with DVT and 0.4% (2/451) of the patients were confirmed with PE. In addition, 4.9% (22/451) of the patients were suffered from superficial vein thrombosis such as calf intermuscular vein thrombosis (Table 1).

Baseline Demographic and Clinical Characteristic
The baseline demographic and clinical characteristics of the patients are displayed in Table 1. There were no statistical differences in body mass index (BMI), prostate volume, creatinine, total prostate-specific antigen (TPSA), free prostate-specific antigen (FPSA)/(TPSA), preoperative D-dimer, international prostate symptom score (IPSS), quality of life (QOL) score, hypertension, and family history of VTE between the VTE group and non-VTE group. Meanwhile, some other potential risk factors were showed differences significantly between VTE patients and non-VTE patients, such as postoperative hemoglobin (Hb), postoperative D-dimer, postoperative/preoperative D-dimer, Caprini score, operation duration, diabetes mellitus, history of surgery (<1 month), history of VTE, and postoperative bladder hematoma (Table 1).
TABLE 1 | Baseline demographic and clinical characteristics.

| Variables | Total patients | VTE | Non-VTE | P-value |
|-----------|----------------|-----|---------|---------|
| Count     | 451            | 36  | 415     | –       |
| Age (years), median (IQR) | 68 (64–74) | 70 (68–77) | 68 (64–72) | 0.049 |
| BMI (kg/m²), mean ± SD | 23.47 ± 3.05 | 22.71 ± 2.18 | 23.54 ± 3.12 | 0.124 |
| Prostate volume (ml), median (IQR) | 52.20 (39.48–70.90) | 55.80 (42.70–76.40) | 52.85 (38.98–73.43) | 0.857 |
| Creatinine (µmol/L), median (IQR) | 87.0 (79.2–97.0) | 93.6 (82.0–103.0) | 86.9 (79.0–95.0) | 0.116 |
| Hb (g/L), median (IQR) | Preoperative | 137 (128–145) | 133 (128.75–145.00) | 136 (122.00–144.25) | 0.318 |
| | Postoperative | 130 (120–138) | 123 (106–135) | 130 (120–138.25) | 0.016 |
| | ΔHb | 7 (1–13) | 11 (4–18) | 6 (0–12) | 0.005 |
| TPSA (ng/ml), median (IQR) | 3.95 (2.08–7.11) | 4.73 (2.66–8.03) | 3.98 (2.10–6.87) | 0.347 |
| FPSA/TPSA, median (IQR) | 0.20 (0.15–0.25) | 0.22 (0.17–0.29) | 0.20 (0.15–0.25) | 0.114 |
| D-dimer (mg/L), median (IQR) | Preoperative | 0.15 (0.11–0.24) | 0.16 (0.12–0.26) | 0.15 (0.10–0.23) | 0.123 |
| | Postoperative | 1.00 (0.47–2.14) | 2.53 (1.26–5.62) | 0.92 (0.45–2.00) | 0.000 |
| | Postoperative/preoperative | 6.59 (3.08–14.04) | 11.64 (4.53–27.51) | 6.21 (3.00–13.60) | 0.019 |
| | Caprini score, median (IQR) | 5 (5–6) | 6 (5–8) | 5 (5–6) | 0.000 |
| | Operation duration (min), median (IQR) | 63.50 (42.75–85.00) | 65 (55–100) | 60 (45–85) | 0.038 |
| IPSS score, median (IQR) | Preoperative | 22 (20–24) | 21 (19–23) | 22 (20–24) | 0.318 |
| | Postoperative | 14 (12–15) | 14 (12–16) | 14 (12–16) | 0.678 |
| QOL score, median (IQR) | Preoperative | 5 (4–5) | 5 (4–5) | 5 (4–5) | 0.764 |
| | Postoperative | 2 (1–3) | 2 (1–3) | 2 (1–3) | 0.649 |
| Hypertension | 176 (39.02%) | 13 (36.11%) | 163 (39.27%) | 0.709 |
| Diabetes Mellitus | 54 (11.97%) | 8 (22.22%) | 46 (11.08%) | 0.049 |
| History of surgery (<1 mon) | 26 (5.76%) | 5 (13.89%) | 21 (5.06%) | 0.030 |
| History of VTE | 10 (2.22%) | 5 (13.89%) | 5 (1.20%) | 0.000 |
| Family history of VTE | 6 (1.33%) | 1 (2.78%) | 5 (1.20%) | 0.431 |
| Postoperative bladder hematoma | 29 (6.43%) | 10 (27.78%) | 29 (4.5%) | 0.000 |

VTE, venous thromboembolism; BMI, body mass index; Hb, Hemoglobin; TPSA, total prostate specific antigen; FPSA, free prostate specific antigen; IPSS, international prostate symptom score; QOL, quality of life.

Note: Some independent variables without statistical significance are not presented in this table, including preoperative hematuria, preoperative urinary tract infections, arthritis, lower limb fracture, lower limb varicose veins, preoperative history of anticoagulant, COPD, heart failure, coronary heart disease, history of tumor, history of cerebral infarction and anemia. Bold values means statistically significant.

Univariate Logistic Regression Analysis

Univariate logistic regression analysis was further performed to detect the risk factors associated with VTE following TURP. We found that older than 65 years of age, postoperative Hb ≤110 g/L, decreased value of Hb in surgery >10.5 g/L, postoperative D-dimer >1.25 mg/L, postoperative/preoperative D-dimer >5, Caprini score >6, surgical duration of >60 min, having a history of surgery within 1 month, having a history of VTE and complicating with a postoperative bladder hematoma were possible risk factors of VTE (Table 2).

Multivariate Logistic Regression Analysis and Nomogram Prediction Model

To determine the independent effects of risk factors for postoperative VTE following TURP, the multivariate logistic regression and multivariate stepwise logistic regression analyses were performed. In multivariate logistic regression analysis, history of VTE (adjusted odds ratio [aOR] = 8.597, 95% CI = 1.468–50.348), complicating with postoperative bladder hematoma (aOR = 4.250, 95% CI = 1.293–13.971), and D-dimer >1.25 mg/L (aOR = 4.558, 95% CI = 1.413–14.699) were found to be the independent risk factors of VTE after TURP. Following this, the multivariate stepwise logistic regression analysis was performed. Considering that age is an important risk factor for VTE, we took age into consideration in multivariate stepwise logistic regression analysis. The results showed that history of VTE (aOR = 10.980, 95% CI = 2.265–53.223), complicated with postoperative bladder hematoma (aOR = 6.302, 95% CI = 2.265–17.532), D-dimer >1.25 mg/L (aOR = 4.402, 95% CI = 1.798–10.774), and age >65 (aOR = 3.106, 95% CI = 1.084–8.893) were independent risk factors of VTE underwent TURP (Table 3). Furthermore, a nomogram prediction model was established to calculate the cumulative probability of VTE according to the results of multivariate stepwise logistic regression analysis.
### TABLE 2 | Univariate logistic regression analysis of risk factors associated with VTE following TURP.

|                      | VTE (n = 36) | Non-VTE (n = 415) | P-value | Exp (B) | Exp (B) 95% CI |
|----------------------|--------------|-------------------|---------|---------|----------------|
| **Age (years)**      |              |                   |         |         |                |
| ≤ 65                 | 6            | 141               | 0.039   | 2.582   | 1.050–6.350    |
| > 65                 | 30           | 274               |         |         |                |
| **Postoperative Hb (g/L)** |            |                   |         |         |                |
| > 110                | 26           | 367               | 0.005   | 3.069   | 1.391–6.769    |
| ≤ 110                | 10           | 46                |         |         |                |
| **ΔHb (g/L)**        |              |                   |         |         |                |
| ≤ 10.5               | 16           | 286               | 0.004   | 2.793   | 1.401–5.566    |
| > 10.5               | 20           | 128               |         |         |                |
| **Postoperative D-dimer** |            |                   |         |         |                |
| ≤ 1.25               | 8            | 152               | 0.000   | 4.515   | 1.951–10.445   |
| > 1.25               | 24           | 101               |         |         |                |
| **Postoperative/preoperative D-dimer** |         |                   |         |         |                |
| ≤ 5                  | 8            | 112               | 0.042   | 2.383   | 1.031–5.507    |
| > 5                  | 24           | 141               |         |         |                |
| **Intraoperative blood loss (ml)** |     |                   |         |         |                |
| ≤ 35                 | 11           | 262               | 0.000   | 3.970   | 1.900–8.295    |
| > 35                 | 25           | 150               |         |         |                |
| **Caprini score**    |              |                   |         |         |                |
| ≤ 6                  | 22           | 362               | 0.000   | 4.346   | 2.096–9.014    |
| > 6                  | 14           | 53                |         |         |                |
| **Surgery duration (min)** |        |                   |         |         |                |
| ≤ 60                 | 11           | 212               | 0.020   | 2.385   | 1.144–4.974    |
| > 60                 | 25           | 202               |         |         |                |
| **Diabetes Mellitus**| 8 (22.22%)   | 46 (11.08%)       | 0.054   | 2.292   | 0.986–5.327    |
| **History of surgery (<1 mon)** | 5 (13.89%) | 21 (5.06%)        | 0.038   | 3.018   | 1.065–8.553    |
| **History of VTE**   | 5 (13.89%)   | 5 (1.20%)         | 0.000   | 13.226  | 3.633–48.154   |
| **Postoperative bladder hematoma** | 10 (27.78%) | 29 (4.5%)         | 0.000   | 8.016   | 3.384–18.990   |

VTE, venous thromboembolism; ΔHb, preoperative hemoglobin—postoperative hemoglobin.

Bold values means statistically significant.

(Figure 1). The total score is the sum of the scores of the four risk factors (age > 65, D-dimer > 1.25 mg/L, history of VTE, and postoperative bladder hematoma), and the VTE risk rate corresponds to the corresponding total score. The predictive ability of the model was evaluated by the C-index (0.793, 95% CI 0.719–0.867, p < 0.0001).

**DISCUSSION**

Venous thromboembolism is a common and potentially fatal complication that happened after surgery, and it has attracted more and more attention in recent years. In this research, we found that the incidence of VTE following TURP was 8.0%, the incidence of DVT was 2.7%, the incidence of PE was 0.4%, and 4.9% for superficial vein thrombosis. This finding was surprising. Because the previous study reported that the incidence of VTE after urological non-oncological surgery was maintained at a range of 0.5–1.4% (13–17). Thus, the urologist seems to pay little attention to VTE in patients after TURP. However, the incidence of VTE in recent years is not as low as reported. The results of our study showed that the incidence of VTE is much higher than previously reported. This may be due to the high postoperative ultrasound screening rate (60%) in our urology department. While, in another research, ultrasonography or venous angiography was performed when patients exhibited VTE-related symptoms or fibrinogen elevation (18, 19). This suggests that many asymptomatic patients with VTE may have been missed. Another reason that caused the high incidence of VTE in our study may be the high proportion of aged patients. The median age in our study was 68 years old and the VTE group patients’ median age was 70 years old. We found that age over 65 was an independent risk factor of VTE through the multivariate stepwise logistic regression analysis. This is ∼10 years earlier than the age of 75 indicated by the EAU (20). We speculate that this is caused by the lower proportion (20%) of the older patients (>75 years old) in our cohort. As we all know, advanced age is an important risk factor for VTE. Borow et al. reported that the incidence of DVT in patients aged 40–60, older than 71 were 20 and 62.5%, respectively. Though the incidence of DVT was maintained at a low rate among patients who have received thromboprophylaxis therapy, the incidence doubled in patients aged 60–70 years old and increased three times in patients older than 71 (21). Naess et al. revealed that
TABLE 3 | Multivariate and multivariate stepwise logistic regression analysis of risk factors associated with VTE following TURP.

| Risk factors                        | Multivariate logistic regression | Multivariate stepwise logistic regression |
|-------------------------------------|---------------------------------|------------------------------------------|
|                                     | P-Value | aOR      | 95% CI         | P-value | aOR      | 95% CI         |
| Diabetes Mellitus                   | 0.238   | 1.892    | 0.656–5.453    | 0.003   | 10.980   | 2.266–53.223   |
| History of VTE                      | 0.017   | 8.597    | 1.468–50.348   | 0.000   | 6.302    | 2.266–17.532   |
| History of surgery (<1 mon)         | 0.417   | 1.777    | 0.444–7.111    | 0.035   | 3.106    | 1.084–8.893    |
| Postoperative bladder hematoma      | 0.017   | 4.250    | 1.293–13.971   | 0.001   | 6.302    | 2.266–17.532   |
| Age > 65 (years)                    | 0.097   | 2.506    | 0.847–7.417    | 0.035   | 3.106    | 1.084–8.893    |
| D-dimer > 1.25 (mg/L)               | 0.011   | 4.558    | 1.413–14.699   | 0.000   | 6.302    | 2.266–17.532   |
| Postoperative Hb (g/L)              | 0.914   | 1.068    | 0.320–3.571    | 0.000   | 6.302    | 2.266–17.532   |
| Postoperative/preoperative D-dimer   | 0.876   | 0.908    | 0.272–3.037    | 0.000   | 6.302    | 2.266–17.532   |
| Caprini score (≥ 6)                 | 0.541   | 1.321    | 0.541–3.227    | 0.000   | 6.302    | 2.266–17.532   |
| Operation duration > 60 (min)       | 0.218   | 1.744    | 0.720–4.224    | 0.000   | 6.302    | 2.266–17.532   |

Bold values means statistically significant.

FIGURE 1 | Nomogram to predict the probability of VTE after TURP. VTE, venous thromboembolism; TURP, transurethral resection of the prostate.

the incidence of VTE increased exponentially with age. Incidence in subjects aged 70 years or above was more than three times higher than those in subjects aged 45–69 years, which again were three times higher than the incidence in subjects aged 20–44 years (22). There are many reasons for elderly patients prone to suffer VTE. An abnormal high level of coagulation factors in the blood is a possible reason (23). Meanwhile, Koster’s research recommended that high factor VIII concentrations represent a clear increase in the risk of thrombosis (24). Other possible reasons include poor mobility, lower cardiorespiratory fitness, and more complications. D-dimer is the simplest fibrin degradation product. An increased level of D-dimer indicates a hypercoagulable state in the blood. So, in our department, a D-dimer test was performed routinely to detect VTE due to its high sensitivity. The results of this study showed that the level of D-dimer > 1.25 mg/L was an independent risk factor. The critical value of D-dimer was much higher than previously reported (6, 25). This difference may result from the high proportion of aged patients in this study. As is known to all, D-dimer level was not only increased in most of the patients with VTE but the level was also influenced by several other factors, such as aging, surgery, cardiovascular diseases, and so on (26–28). To reduce the influence of advanced age on the diagnostic specificity of D-dimer, some researchers have proposed to adjust the threshold of D-dimer to predict VTE based on age (age × 10 μg/L) (29). Moreover, the studies of Schouten and Han have confirmed that the age-adjusted cut-off of D-dimer values can improve its diagnostic specificity without affecting sensitivity (30, 31). So, in elderly patients after TURP, a mild elevated D-dimer (< 1.25 mg/L) may not be considered as a risk factor, but they are still recommended to perform D-dimer test after TURP owing to its high sensitivity. In this study, we found that having a history of VTE was an independent risk factor of VTE, which is consistent with previous studies (32, 33). Meanwhile, the American College of Chest Physicians (ACCP-9), EAU, and American Urological Association (AUA) confirmed that the history of VTE was an important risk factor (20, 34, 35). So, prior VTE history should be emphasized in risk stratification for patients after TURP. Postoperative bladder hematoma was a risk factor of VTE following TURP according to the multivariate stepwise logistic analysis. If the color of the continuous bladder irrigation is bright red and combined with a decreased Hb after TURP, the bladder ultrasound will be performed to confirm whether there is a bladder hematoma. Patients with bladder hematoma after TURP have a significantly increased risk of VTE. This may be due to the longer time spent in bed for these parts of patients. Furthermore, bleeding can lead to activation of the coagulation system and made the blood of these patients in a hypercoagulable state. Intriguingly, there was no significant difference in the Carprini score between the VTE group and the non-VTE group.
in our cohort (after the multivariate stepwise logistic regression analysis). Age over 60 is defined as 2 points and surgery is defined as 1 or 2 points according to the Caprini risk assessment model (RAM). However, most of the patients in our study were older than 60. So, their baseline Caprini score was at least 3 points (age >60 and underwent TURP). This means that most of these patients were at moderate risk of VTE in the Caprini RAM. Another indicator without significant difference is BMI. This is because it is not easy to find elderly individuals whose BMI was more than 35 in our department. The highest BMI was 33.65 among all patients included in this study. Further studies on these two factors are needed. Compared to transurethral resection of bladder tumor (TURBT), we speculate that the development of VTE following TURP may be related to elderly age, the prolonged lithotomy position procedure, longer duration of bed rest after surgery, higher risk of bleeding, etc. Prolonged lithotomy position procedure may lead to poor lower extremity venous reflux and alter hemodynamic states. This may increase the risk of thrombosis. In addition, perioperative bleeding can activate the coagulation system cause a higher possibility of VTE. However, as for TURBT, the main risk factor of VTE is the tumor. Various studies have shown that the tumor can obviously increase the risk of VTE (36, 37). As far as we know, this is the first cohort study specifically focusing on VTE on TURP. We established a nomogram prediction model of VTE for patients who underwent TURP. It is an auxiliary prevention tool of VTE beneficial to clinical practice. However, we must propose that there are some limitations to this study. First, this is a single-center retrospective study. Second, the number of patients included in this study is small. Third, the period of observation for patients with VTE was only during hospitalization. The long-term follow-up for discharged VTE patients was still needed.

Considering the limitations of our study, further large-scaled and multicenter studies are urgently needed to confirm the result.

**CONCLUSION**

The incidence of VTE is severely underestimated in patients following TURP. A lot of asymptomatic VTEs have been overlooked. On the other hand, history of VTE, postoperative bladder hematoma, age > 65 (years), and D-dimer > 1.25 (mg/L) are independent risk factors. So, it is important that VTE is detected and diagnosed early in patients after TURP according to these risk factors. Nevertheless, further verifications based on the results of large-scaled studies are still needed.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**AUTHOR CONTRIBUTIONS**

ZT and ZWa conceived and designed the study. ZZ, ZWu, KL, QZ, HL, XL, and GW collected the data. ZZ, ZWu, and ZWa analyzed and were involved in the interpretation of data. ZZ and ZWu drafted the manuscript. ZT, ZWa, ZZ, and ZWu made final approval of the version to be published. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the Project from the National Health Commission of Hunan Province to Tang Zhengyan (B2019185).

**REFERENCES**

1. Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. (2016) 2:16031. doi: 10.1038/nrdp.2016.31
2. McVary KT, Roeherborn CG, Ayins AL, Barry MJ, Bruskewitz RC, Donnell RF; et al. Update on AUA guideline on the management of benign prostatic hypertrophy. J Urol. (2011) 5:1793–803. doi: 10.1016/j.juro.2011.01.074
3. Scarpa RM, Carrieri G, Gussoni G, Tubaro A, Conti G, Pagliarulo V, et al. Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. Eur Urol. (2007) 51:130–35; discussion 136. doi: 10.1016/j.euro.2006.07.014
4. Alberts BD, Woldu SL, Weinberg AC, Danzig MR, Korets RK, Badani KK. Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations. Urology. (2014) 4:799–806. doi: 10.1016/j.urology.2014.05.055
5. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. (2013) 126:832.e13-21. doi: 10.1016/j.amjmed.2013.02.024
6. Wu QZ, Li KX, Zhu Q, Li HZ, Tang ZY, Wang Z. Application value of D-dimer testing and Caprini risk assessment model (RAM) to predict venous thromboembolism (VTE) in Chinese non-oncological urological inpatients: a retrospective study from a tertiary hospital. Transl Androl Urol. (2020) 5:1904–11. doi: 10.21037/tau-20-320
7. Zeng H, Gao M, Chen J, Cui Y, Huang F, Zeng F, et al. Incidence and risk factors of venous thromboembolism after percutaneous nephrolithotomy: a single-center experience. World J Urol. (2021) 39:3571–7. doi: 10.1007/s00345-021-03658-w
8. Tikkinen KAO, Craige S, Agarwal A, Siemieniuk RAC, Cartwright R, Violette PD, et al. Procedure-specific risks of thrombosis and bleeding in urological non-cancer surgery: systematic review and meta-analysis. Eur Urol. (2018) 2:236–41. doi: 10.1016/j.eururo.2017.02.025
9. Golash A, Collins PW, Kynaston HG, Jenkins BJ. Venous thromboembolic prophylaxis for transurethral prostatectomy: practice among British urologists. J R Soc Med. (2002) 3:130–31. doi: 10.1258/jrsm.9 5.3.130
10. EAU Guidelines on Thromboprophylaxis in Urological Surgery (2017). Available online at: https://uroweb.org/guideline/thromboprophylaxis/#3 (accessed March 23, 2017).
11. Anderson DR, Morango GP, Bennett C, Dentali F, Francis CW, Garcia DA, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. (2019) 23:8398–944. doi: 10.1182/bloodadvances.2019009975
12. Wang P, Kandemir U, Zhang B, Wang B, Li J, Zhuang Y, et al. Incidence and risk factors of deep vein thrombosis in patients with pelvic and acetabular fractures. Clin Appl Thromb Hemost. (2019) 25. doi: 10.1177/1076029619845066
13. Turna B, Stein RJ, Smaldone MC, Santos BR, Kefer JC, Jackman SV, et al. Safety and efficacy of flexible ureterorenoscopy and holmium:YAG lithotripsy for intrarenal stones in anticoagulated cases. J Urol. (2008) 4:1415–19. doi: 10.1016/j.juro.2007.11.076
Zheng et al.

14. Sofer M, Lidawi G, Keren-Paz G, Yehiely R, Beri A, Matzkin H. Tubeless percutaneous nephrolithotomy: first 200 cases in Israel. Isr Med Assoc J. (2010) 3:164–7. Available online at: https://www.ima.org.il/MedicinIMAJ/viewarticle.aspx?year=2010&month=03&page=164

15. Mueller MG, Pilecki MA, Catanzarite T, Jain U, Kim YJ, Kenton K. Venous thromboembolism in reconstructive pelvic surgery. Am J Obstet Gynecol. (2014) 2:552.e151–6.303. doi: 10.1016/j.ajog.2014.07.031

16. Gordon D, Gold R, Pauzner D, Lessing JB, Groutz A. Tension-free vaginal tape in the elderly is it a safe procedure? Urology. (2005) 3:479–82. doi: 10.1016/j.urology.2004.09.059

17. Mamoulakis C, Efthimiou I, Kazoulis S, Christoulakis I, Sofras F. The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. World J Urol. (2011) 2:205–10. doi: 10.1007/s00345-010-0566-y

18. Righini M, Robert-Ebadi H, Le Gal G. Diagnosis of acute pulmonary embolism. J Thromb Haemost. (2017) 7:1251–61. doi: 10.1111/jth.13694

19. Parakh RS, Sabath DE. Venous thromboembolism: role of the clinical laboratory in diagnosis and management. J Appl Lab Med. (2019) 5:870–82. doi: 10.1373/jalm.2017.025734

20. Tikkinen KAO, Gould MK, Naspro R, Novara G, Sandset PM, Violette PD, et al. EAU–Guidelines on-Thromboprophylaxis-2019. EAU (2019).

21. Borow M, Goldson H. Postoperative venous thrombosis. Evaluation of five methods of treatment. Am J Surg. (1981) 2:245–51. doi: 10.1016/0002-9610(81)90168-9

22. Naess IA, Christiansen SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thromboembolism: a population-based study. J Thromb Haemost. (2007) 4:692–9. doi: 10.1111/j.1138-7836.2007.02450.x

23. Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walsdon J, et al. Inflammation and coagulation factors in persons 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol. (2002) 4:419–24. doi: 10.1016/S0002-9199(01)02264-0

24. Koster T, Blann AD, Brist E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. (1995) 8943:152–5. doi: 10.1016/S0140-6736(95)90166-3

25. Shi A, Huang J, Wang X, Li M, Zhang J, Chen Y, et al. Postoperative D-dimer predicts venous thromboembolism in patients undergoing urologic tumor surgery. Urol Oncol. (2018) 6:307, e315–07. e321. doi: 10.1016/j.eururo.2017.03.008

26. Kabrhel C, Mark Courtney D, Camargo CA Jr, Plewa MC, Nordenholz KE, et al. Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med. (2010) 6:589–97. doi: 10.1111/j.1553-2712.2010.00765.x

27. Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghysen A, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. (2014) 11:1117–24. doi: 10.1001/jama.2014.2135

28. Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost. (2012) 7:673–82. doi: 10.1055/s-0032-1326782

29. Douma RA, le Gal G, Söhn M, Righini M, Kamphuisen PW, Perrier A, et al. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ. (2010) 340:c1475. doi: 10.1136/bmj.c1475

30. Schouten HJ, Geersing GJ, Koek HL, Zaithoff NP, Janssen KJ, Douma RA, et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-analysis. BMJ. (2013) 345:f2492. doi: 10.1136/bmj.f2492

31. Han C, Zhao Y, Cheng W, Yang J, Yuan J, Zheng Y, et al. The performance of age-adjusted D-dimer cut-off in Chinese outpatients with suspected venous thromboembolism. Thromb Res. (2015) 4:739–43. doi: 10.1016/j.thromres.2015.07.024

32. Pedersen MH, Wahlsen LR, Granborg H, Gislason GH, Petersen MM, Bonde AN. Symptomatic venous thromboembolism after achilles tendon rupture: a nationwide Danish cohort study of 28,546 patients with achilles tendon rupture. Am J Sports Med. (2019) 13:3229–37. doi: 10.1177/0363546519876054

33. Kahr HS, Christiansen OB, Høgdall C, Grove A, Mortensen RN, Torp-Pedersen C, et al. Endometrial cancer does not increase the 30-day risk of venous thromboembolism following hysterectomy compared to benign disease. A Danish National Cohort Study. Gynecol Oncol. (2019) 1:112–18. doi: 10.1016/j.ygyno.2019.07.022

34. Forrest JR, Clemens JQ, Finamore P, Levellée R, Lippert M, Pisters L, et al. AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol. (2009) 3:1170–7. doi: 10.1016/j.juro.2008.12.027

35. MK G, DA G, SM W, PJ K, JI A, JA H, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. (2012) 141(Suppl. 2):e227S–778. doi: 10.1378/chest.11-2297

36. Shi J, Ye J, Zhuang X, Cheng X, Fu R, Zhao A. Application value of Caprini risk assessment model and elevated tumor-specific D-dimer level in predicting postoperative venous thromboembolism for patients undergoing surgery of gynecologic malignancies. J Obstet Gynaecol Res. (2019) 3:657–64. doi: 10.1111/jog.13832

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zheng, Wu, Li, Zhu, Li, Liu, Wang, Tang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.